Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV.
Kei Muro
Honoraria - Chugai Pharma; Yakult Honsha
Research Funding - Chugai Pharma; Yakult Honsha
Takeharu Yamanaka
Honoraria - Chugai Pharma; Yakult Honsha
Mitsukuni Suenaga
No relevant relationships to disclose
Tomohiro Nishina
Honoraria - Chugai Pharma; Yakult Honsha
Hisateru Yasui
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Takashi Ura
No relevant relationships to disclose
Tadamichi Denda
No relevant relationships to disclose
Junichi Ikeda
No relevant relationships to disclose
Taito Esaki
Honoraria - Chugai Pharma; Yakult Honsha
Research Funding - Yakult Honsha
Hogara Nishisaki
No relevant relationships to disclose
Yoshinao Takano
No relevant relationships to disclose
Ken Kondo
No relevant relationships to disclose
Koji Takeda
Honoraria - Chugai Pharma; Yakult Honsha
Yasuo Takahashi
No relevant relationships to disclose
Kazuya Endo
No relevant relationships to disclose
Yasuyuki Sugiyama
No relevant relationships to disclose